Key result
Intracoronary nitroglycerine administration relieved coronary stenosis and prevented unnecessary percutaneous coronary intervention in 7.5% of patients, with multivessel disease strongly predicting nonresponse (OR 16.26).
Why the study?
Despite current guideline recommendations, intracoronary administration of nitroglycerine during coronary angiography is often neglected, leading researchers to investigate its effect on relieving coronary stenosis in PCI candidates.
Does intracoronary nitroglycerin improve coronary artery stenosis and prevent unnecessary PCI in candidates for percutaneous coronary intervention?
Cohort (n=360)
No
Does intracoronary nitroglycerin improve coronary artery stenosis and prevent unnecessary PCI in candidates for percutaneous coronary intervention?
Routine intracoronary nitroglycerin administration during diagnostic angiography can relieve coronary vasospasm and safely defer PCI in approximately 7.5% of patients.
May support deferring PCI after nitroglycerin in select cases; leaves open need for randomized confirmation.
BACKGROUND: Despite the recommendation of the current guidelines, intracoronary administration of nitroglycerine during coronary angiography is often neglected. We investigated the effect of intra-coronary nitroglycerin on the relief of coronary artery stenosis in the candidates for percutaneous coronary intervention (PCI). METHODS: We included patients with angina pectoris or myocardial infarction who were candidates for PCI. In the coronary angiography, the culprit vessel involved was evaluated, and bolus nitroglycerin at a dose of 25-200 mcg was injected into the affected coronary artery. A significant change in the percentage of coronary artery stenosis was considered a positive response, and these patients were then compared with patients who did not have a substantial change in the percentage of stenosis at the same time. Univariate analysis and then multivariate logistic regression analysis was performed to determine the predictors of response to intracoronary nitroglycerin. RESULTS: Among 360 patients, 27 (7.5%) responded to nitroglycerine, and 333 (92.5%) were non-responsive. The mean age of patients was 60.2 ± 11.6 years, ranging from 23 to 93 years, and 265 (73.6%) were men. The study groups were not significantly different in the baseline demographic characteristics. The presence of multivessel disease (Odds ratio (OR) = 16.26, 95% confidence interval (CI):2.07-127.6; P = 0.008) and stenosis in the left circumflex artery (OR = 3.62, 95% CI: 1.03-12.70; P = 0.044) were the independent predictors for nonresponse to nitroglycerine, leading to PCI. CONCLUSION: In some cases, especially those without multivessel diseases, intracoronary nitroglycerine administration can efficiently relieve coronary stenosis and prevent unnecessary PCI.
No takes yet. Share an insight, caveat, or question.
Nasiri-Partovi et al. (2022) conducted a cohort in Coronary artery disease (candidates for percutaneous coronary intervention) (n=360). Intracoronary nitroglycerine was evaluated on Response to nitroglycerine (reduction of stenosis below 70% of the lumen preventing planned PCI). Intracoronary nitroglycerine administration relieved coronary stenosis and prevented unnecessary percutaneous coronary intervention in 7.5% of patients, with multivessel disease strongly predicting nonresponse (OR 16.26).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: